Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Immunotherapy and Other Nontargeted Approaches for Lung Cancer
Lung Cancer Update
00:00
The Importance of Immunotherapy in Oncology
30% of our audience has been in oncology less than 10 years. It's only 8 years ago that the first I.O. was approved for Olamab in second-line therapy. In terms of immunotherapy, a whole set of different toxicity issues to consider just a completely new world.
Transcript
Play full episode
